HN2000000225A - PHARMACEUTICALLY ACTIVE COMPOUNDS - Google Patents
PHARMACEUTICALLY ACTIVE COMPOUNDSInfo
- Publication number
- HN2000000225A HN2000000225A HN2000000225A HN2000000225A HN2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A HN 2000000225 A HN2000000225 A HN 2000000225A
- Authority
- HN
- Honduras
- Prior art keywords
- active compounds
- pharmaceutically active
- pharmaceutically
- veterinarily acceptable
- compounds
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de fórmula (I): en la que R1, R2, R4 y R13 son como se definen o una sal farmacéutica o veterinariamente aceptable o polimorfo del mismo, o un solvato farmacéutica o veterinariamente aceptable o profármaco del mismo: son inhibidores potentes y selectivos de TIPO 5 CYCLIC GUANOSINE 3'', 5''-monofosfato fosfodiesterasa (cGMP PDE5) y tienen utilidad en el tratamiento de, entre otros, la disfunción eréctil masculina (MED) y la disfunción sexual femenina (DSF).The compounds of formula (I): wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable or polymorphic salt thereof, or a pharmaceutically or veterinarily acceptable solvate or prodrug thereof: they are potent inhibitors and selective TYPE 5 CYCLIC GUANOSINE 3 '', 5 '' - monophosphate phosphodiesterase (cGMP PDE5) and are useful in the treatment of, among others, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924063.2A GB9924063D0 (en) | 1999-10-11 | 1999-10-11 | Pharmaceutically active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2000000225A true HN2000000225A (en) | 2001-04-16 |
Family
ID=10862547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2000000225A HN2000000225A (en) | 1999-10-11 | 2000-10-05 | PHARMACEUTICALLY ACTIVE COMPOUNDS |
Country Status (4)
Country | Link |
---|---|
GB (1) | GB9924063D0 (en) |
HN (1) | HN2000000225A (en) |
UA (1) | UA72773C2 (en) |
ZA (1) | ZA200202763B (en) |
-
1999
- 1999-10-11 GB GBGB9924063.2A patent/GB9924063D0/en not_active Ceased
-
2000
- 2000-10-05 HN HN2000000225A patent/HN2000000225A/en unknown
- 2000-11-10 UA UA2002042898A patent/UA72773C2/en unknown
-
2002
- 2002-04-09 ZA ZA200202763A patent/ZA200202763B/en unknown
Also Published As
Publication number | Publication date |
---|---|
UA72773C2 (en) | 2005-04-15 |
GB9924063D0 (en) | 1999-12-15 |
ZA200202763B (en) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23198A3 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS | |
TR200003039T2 (en) | Pirazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunctions | |
PE20040197A1 (en) | PYRAZOLOPYRIDINES SUBSTITUTED WITH CARBAMATE | |
NO20015275D0 (en) | Unit dosage form | |
HN2000000225A (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS | |
ECSP003703A (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS | |
UY26387A1 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS | |
PA8523501A1 (en) | CRYSTAL THERAPEUTIC AGENT | |
MY131573A (en) | Use of pde5 inhibitors for the treatment of premature ejaculation | |
AR030681A1 (en) | PIRAZOLO COMPOUNDS [4,3-] PIRIMIDIN-7-ONAS, PHARMACEUTICAL COMPOSITION, VETERINARY FORMULATION, USE IN THE MANUFACTURE OF MEDICINAL PRODUCT, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS, INTERMEDIARY COMPOUNDS AND THEIR PREPARATION | |
IL165411A0 (en) | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |